Medtronic extravascular icd meets global pivotal clinical trial's safety and effectiveness endpoints

Late-breaking data presented at esc congress 2022 and simultaneously published in the new england journal of medicine confirms implant procedure safety and defibrillation success dublin and barcelona, spain , aug. 28, 2022 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced that its investigational ev icd™ system – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial. findings from the extravascular implantable cardioverter defibrillator (ev icd) pivotal study were presented as late-breaking science today at the european society of cardiology (esc) congress 2022 in barcelona and simultaneously published in the new england journal of medicine.
MDT Ratings Summary
MDT Quant Ranking